The angiographic and clinical benefits of mibefradil in the coronary slow flow phenomenon

Mangieri, 1996, Slow coronary flow, Cathet Cardiovasc Diagn, 37, 375, 10.1002/(SICI)1097-0304(199604)37:4<375::AID-CCD7>3.0.CO;2-8 Mosseri, 1986, Histologic evidence for small-vessel coronary artery disease in patients with angina and patent large coronary arteries, Circulation, 74, 964, 10.1161/01.CIR.74.5.964 Beltrame, 2003, Coronary hemodynamic and metabolic studies of the coronary slow flow phenomenon, Am Heart J, 146, 84, 10.1016/S0002-8703(03)00124-8 Beltrame, 2002, The coronary slow flow phenomenon—a new coronary microvascular disorder, Cardiology, 97, 197, 10.1159/000063121 Diver, 1994, Clinical and arteriographic characterization of patients with unstable angina without critical coronary arterial narrowing (from the TIMI-IIIA trial), Am J Cardiol, 74, 531, 10.1016/0002-9149(94)90739-0 Chesebro, 1987, Thrombolysis In Myocardial Infarction (TIMI) trial, phase I, Circulation, 76, 142, 10.1161/01.CIR.76.1.142 Prueksaritanont, 1999, Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors, Br J Clin Pharmacol, 47, 291, 10.1046/j.1365-2125.1999.00903.x Gibson, 1996, TIMI frame count, Circulation, 93, 879, 10.1161/01.CIR.93.5.879 Ware, 1992, The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection, Med Care, 30, 473, 10.1097/00005650-199206000-00002 Jones, 1989 Kurtoglu, 2001, Usefulness of oral dipyridamole therapy for angiographic slow coronary artery flow, Am J Cardiol, 87, 777, 10.1016/S0002-9149(00)01503-4 Gustafsson, 2001, Conducted vasoconstriction in rat mesenteric arterioles, Am J Physiol Heart Circ Physiol, 280, H582, 10.1152/ajpheart.2001.280.2.H582 Becquemont, 1999, Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics, Fundam Clin Pharmacol, 13, 232, 10.1111/j.1472-8206.1999.tb00344.x